More M&A For Astellas As It Pursues New Mid-Term Goals?
This article was originally published in PharmAsia News
Executive Summary
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.